Latest Aromatase inhibitor Stories
New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer.
- Several SSRIs more than double risk of cancer recurrence in tamoxifen treated patients - Nearly 30 percent of tamoxifen users take drugs that reduce its effectiveness against breast cancer ORLANDO, Fla., May 30 /PRNewswire-FirstCall/ -- An important new study finds that certain popular antidepressants frequently prescribed to women taking the breast cancer drug tamoxifen more than double the risk of a breast cancer recurrence for those using both medications.
Non-invasive imaging can measure how well patients with the most common form of breast cancer - estrogen receptor positive type - respond to standard aromatase inhibitor therapy after only two weeks and shows similar findings that more invasive needle sampling identifies, according to a poster presentation to be presented at the ASCO annual meeting next week.
SAN ANTONIO, Dec. 15 /PRNewswire/ -- Two leading cancer physicians and researchers affiliated with US Oncology Research gave oral presentations at the 2008 San Antonio Breast Cancer Symposium.
Dense breast tissue contains more cells believed to give rise to breast cancer, compared to non-dense tissue, U.S. researchers said. Dr.
SAN ANTONIO, Dec.
According to a preliminary study reported Thursday at a cancer conference in Texas, new research adds fresh hope that a drug that strengthens bones might also fight breast cancer.
Scientists in the UK published a study on Wednesday claiming they have figured out why some women develop resistance to the most commonly used breast cancer drug, something that raises the risk their tumors will return.
London, UK, and Cambridge, MA: 30 September 2008 - Cancer drug developer Antisoma plc (LSE: ASM; USOTC: ATSMY) today announced that it has started a phase II trial evaluating the addition of AS1402 to the endocrine (hormonal) therapy letrozole in post-menopausal women receiving first-line treatment for advanced breast cancer.
EMERYVILLE, Calif., Sept. 25 /PRNewswire-FirstCall/ -- Bionovo, Inc. will present an abstract in a presentation on their new drug candidate, VG101, for the treatment of vaginal dryness, at the 19th Annual Meeting of the North American Menopause Society in Orlando, Florida on September 26, 2008. Dr.
- The parings of haberdine; also, any kind of fragments.